pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 10·1 min read
save

Biotech industry rebounds as Endpoints 11 awards return in Boston

Sep 10, 2026·read at Endpoints ↗Neutral

The article notes that the Endpoints 11 awards will be unveiled in Boston on the night of September 24, marking the event’s return after a period of industry slowdown.

It reflects on how the biotech sector feels markedly different now compared with 2018, suggesting a broader rebound in activity and optimism.

The piece also invites readers to sign up for free access to the full article and related newsletters, emphasizing limited free content for those interested in the latest industry developments.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “How past Endpoints 11 winners fared as biotech industry rebounded”

read at Endpoints ↗
78 words · retrieved Sep 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 6h agoMerck reports mixed data for Lucentis competitor in diabetic macular edemaEndpoints
  • 7h agoAsahi Kasei lands approval for new HSV treatmentEndpoints
  • 9h agoMirum succeeds in rare liver disease trial; First Tracks delivers in celiacEndpoints
  • 9h agoBristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugsEndpoints
  • 9h agoBrent Saunders out as Bausch + Lomb CEO, an abrupt end to three-year runEndpoints